Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The N-terminus of apolipoprotein B mediates the interaction of atherogenic lipoproteins with endothelial cells
Ainara G. Cabodevilla, Camila Calistru, Waqas Younis, Dimitris Nasias, Tse W.W. Ho, Narasimha Anaganti, Swati Valmiki, Sujith Rajan, Jana Gjini, Rufina Kore, Carmen Hannemann, Nicholas O. Davidson, Tomas Vaisar, Jenny E. Kanter, Karin E. Bornfeldt, Edward A. Fisher, Warren L. Lee, Tobias Madl, M. Mahmood Hussain, Ira J. Goldberg
Ainara G. Cabodevilla, Camila Calistru, Waqas Younis, Dimitris Nasias, Tse W.W. Ho, Narasimha Anaganti, Swati Valmiki, Sujith Rajan, Jana Gjini, Rufina Kore, Carmen Hannemann, Nicholas O. Davidson, Tomas Vaisar, Jenny E. Kanter, Karin E. Bornfeldt, Edward A. Fisher, Warren L. Lee, Tobias Madl, M. Mahmood Hussain, Ira J. Goldberg
View: Text | PDF
Research Article Metabolism Vascular biology

The N-terminus of apolipoprotein B mediates the interaction of atherogenic lipoproteins with endothelial cells

  • Text
  • PDF
Abstract

Apolipoprotein B–containing (APOB-containing) lipoproteins contribute to atherosclerosis by entering the arterial wall through the endothelial cell (EC) surface receptors scavenger receptor-BI (SR-BI) and activin receptor-like kinase 1 (ALK1). We used N-terminal fragments of APOB, molecular modeling, and site-directed mutagenesis to identify and block the binding of chylomicrons and LDL to these receptors in cells and mice. We discovered that different APOB regions interact with SR-BI and ALK1 expressed on ECs. APOB48 lipoproteins were only internalized by SR-BI. A fragment of APOB comprising 18% of the N-terminal sequence, APOB18, reduced the uptake and transport of both chylomicrons and LDL by ECs, whereas a shorter fragment, APOB12, only blocked ALK1-mediated uptake of APOB100-containing lipoproteins. Importantly, overexpressing APOB18 decreased atherosclerosis in hypercholesterolemic mice. These findings identify the N-terminal region of APOB as the cause of atherosclerosis and illustrate an approach to treating or preventing vascular disease.

Authors

Ainara G. Cabodevilla, Camila Calistru, Waqas Younis, Dimitris Nasias, Tse W.W. Ho, Narasimha Anaganti, Swati Valmiki, Sujith Rajan, Jana Gjini, Rufina Kore, Carmen Hannemann, Nicholas O. Davidson, Tomas Vaisar, Jenny E. Kanter, Karin E. Bornfeldt, Edward A. Fisher, Warren L. Lee, Tobias Madl, M. Mahmood Hussain, Ira J. Goldberg

×

Figure 2

ALK1-mediated lipoprotein uptake requires APOB100.

Options: View larger image (or click on image) Download as PowerPoint
ALK1-mediated lipoprotein uptake requires APOB100.
(A) Uptake of chylomi...
(A) Uptake of chylomicrons obtained from APOB48-only mice is inhibited by SR-BI knockdown (KD) with ASO, but not by APOB12 or ALK1 KD with siRNA. (B) Uptake of APOB100 chylomicrons obtained from Apobec1–/– mice is inhibited by competition with APOB12, as well as KD of both SR-BI and ALK1. (C) As with chylomicrons, uptake of APOB48-LDL is inhibited by SR-BI KD but not ALK1 KD or APOB12. (D) Uptake of APOB100 LDL is inhibited by competition with APOB12, as well as KD of both SR-BI and ALK1. Scale bars: 10 μm (A–D). **P < 0.001, ***P < 0.0001, ****P < 0.00001, 1-way ANOVA followed by Dunnett’s post hoc multiple-comparison test against control. (E) Vesicles bearing APOB100 chylomicrons are transported to the base of the cell at a significantly higher rate than vesicles bearing APOB48 chylomicrons. (F) The transcytosis event rate of APOB100 and APOB48 chylomicrons is not significantly different. ****P < 0.00001, unpaired 2-tailed Student’s t test. Results are shown as scatterplots (mean ± SD).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts